Chemed Corporation (NYSE:CHE) Receives Average Rating of “Hold” from Brokerages

Shares of Chemed Corporation (NYSE:CHE) have been given an average recommendation of “Hold” by the six ratings firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $480.25.

CHE has been the subject of a number of recent analyst reports. Bank of America restated a “neutral” rating on shares of Chemed in a report on Wednesday. Royal Bank Of Canada lifted their target price on Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research report on Monday, April 27th. Wall Street Zen lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th.

Trending Headlines about Chemed

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Quarterly results exceeded expectations. Adjusted EPS was $6.06, ahead of the $5.55–$5.60 analyst consensus and up 41.9% from $4.27 a year earlier. Revenue rose 8.8% to $673.3 million, surpassing estimates of approximately $665 million. Chemed Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VITAS drove the strongest growth. Net patient revenue increased 11.9% to $443.3 million, while average daily census rose 6.1% and admissions grew 9.0%. VITAS adjusted EBITDA increased 20.6%, with its margin expanding by 196 basis points to 18.2%. Chemed Reports Second-Quarter 2026 Results
• Positive Sentiment: Full-year earnings guidance was raised. Chemed now expects 2026 adjusted EPS of $25.00 to $25.75, above the prior outlook and the roughly $24.01 consensus estimate. Management attributed the increase primarily to VITAS outperformance, while maintaining its Roto-Rooter outlook. Chemed Raises 2026 Guidance
• Positive Sentiment: Share repurchases provided additional support. Chemed bought back approximately 210,000 shares for $89.8 million during the quarter, signaling confidence in the business and reducing shares outstanding.
• Neutral Sentiment: Roto-Rooter performance was mixed. Revenue rose 3.3% to $229.9 million, but net income and adjusted EBITDA were essentially flat, while the EBITDA margin declined 77 basis points to 21.1%. This limits the segment’s contribution relative to VITAS.
• Negative Sentiment: Insider activity was unfavorable. Company insiders reported five sales and no purchases over the past six months. The activity may temper sentiment, although it is less significant than the earnings beat and raised guidance.

Insider Buying and Selling

In related news, Director Andrea R. Lindell sold 1,347 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the sale, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares of the company’s stock, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 3.33% of the company’s stock.

Institutional Investors Weigh In On Chemed

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in shares of Chemed by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 734 shares of the company’s stock worth $314,000 after buying an additional 22 shares during the period. Cim LLC increased its stake in shares of Chemed by 1.1% during the third quarter. Cim LLC now owns 2,139 shares of the company’s stock valued at $958,000 after buying an additional 24 shares during the period. Eukles Asset Management increased its stake in shares of Chemed by 0.4% during the fourth quarter. Eukles Asset Management now owns 6,056 shares of the company’s stock valued at $2,591,000 after buying an additional 25 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Chemed by 65.3% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after acquiring an additional 32 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Chemed by 9.4% in the first quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after acquiring an additional 35 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Chemed Stock Up 3.9%

Shares of NYSE CHE opened at $537.58 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83. The company has a market cap of $7.13 billion, a P/E ratio of 27.00, a PEG ratio of 1.91 and a beta of 0.52. Chemed has a 1 year low of $365.20 and a 1 year high of $551.68. The firm has a 50-day simple moving average of $463.37 and a two-hundred day simple moving average of $435.25.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a return on equity of 30.64% and a net margin of 10.60%.The firm had revenue of $673.25 million for the quarter, compared to analysts’ expectations of $665.04 million. During the same quarter in the prior year, the firm posted $4.27 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Research analysts anticipate that Chemed will post 22.67 earnings per share for the current year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Thursday, May 28th. Chemed’s dividend payout ratio is currently 13.08%.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.